TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27040694

Group type: EXPERIMENTAL
Intervention: Increased water consumption by 1 glass/d
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Increased consumption of sugar-containing beverages by 1 glass/d
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Promotion of water consumption
Number of subjects: 1987
Study: 24532596

Group type: EXPERIMENTAL
Intervention: Knee extension constraint training for 4 weeks
Number of subjects: 24
Study: 22795046

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy coupled with cognitive behavioral therapy (MET‐CBT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 168
Study: 19540739

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3g/day) for 2 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18499526

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 8
Study: 17512361

Group type: EXPERIMENTAL
Intervention: Multidetector computed tomography (MDCT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional coronary angiography
Number of subjects: 200
Study: 15586800

Group type: EXPERIMENTAL
Intervention: BAC 0.05% (4 x 200 microL/day for 8 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BAC 0.05%
Number of subjects: 16
Study: 11530146

Group type: EXPERIMENTAL
Intervention: Tenecteplase plus enoxaparin
Number of subjects: 6095

Group type: EXPERIMENTAL
Intervention: Tenecteplase plus abciximab
Number of subjects: 6095
Study: 9266876

Group type: EXPERIMENTAL
Intervention: Cefuroxime, 1.5 g IV tid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Cefuroxime, 1.5 g IV bid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Number of subjects: 636
Study: 8302152

Group type: EXPERIMENTAL
Intervention: Continuous succinylcholine infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Single-dose technique
Number of subjects: 15
Study: 3557014

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 283

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 283
Study: 31472028

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 312
Study: 27334521

Group type: EXPERIMENTAL
Intervention: Telemonitoring of home blood pressure measurements (TBPM)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 375
Study: 25514585

Group type: EXPERIMENTAL
Intervention: Full-intervention group (debriefed after scenario sets)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Simulation exposure-only group
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 22889466

Group type: EXPERIMENTAL
Intervention: Intra-umbilical injection of oxytocin (50 IU diluted with normal saline to a total volume of 30 mL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intra-umbilical injection of normal saline (30 mL)
Number of subjects: 58
Study: 21277062

Group type: EXPERIMENTAL
Intervention: midazolam and 1‐mg/kg tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: midazolam and 1‐μg/kg fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: midazolam only
Number of subjects: 60
Study: 19843062

Group type: EXPERIMENTAL
Intervention: Intervention group (education on disease state, medications, and breathing techniques)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 173
Study: 16488953

Group type: EXPERIMENTAL
Intervention: NSAID ophthalmic solution (sodium 2‐amino‐3‐(4‐bromobenzoyl) phenylacetate sesquihydrate) administered for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium hyaluronic acid ophthalmic solution (control group) administered for 12 weeks
Number of subjects: 16
Study: 15602823

Group type: EXPERIMENTAL
Intervention: Chronic childhood constipation (CCC)
Number of subjects: 120
Study: 11128921

Group type: EXPERIMENTAL
Intervention: Gingivoplasty (GP+) performed 2 months after initial grafting
Number of subjects: 6

Group type: COMPARATOR
Intervention: No further treatment (GP-)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gingivoplasty (GP+)
Number of subjects: 6
Study: 9304635

Group type: EXPERIMENTAL
Intervention: 20 mg of oral ketorolac tromethamine (KT) 2 hours prior to surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.03% flurbiprofen sodium (FS) topical solution
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical normal saline
Number of subjects: 63
Study: 8141723

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Standard doses of heparin
Number of subjects: 12000
Study: 3087694

Group type: EXPERIMENTAL
Intervention: Norplant-2 (two covered rods)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Norplant (six capsules)
Number of subjects: 172
Study: 30626347

Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis (1 session per week)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Thrice-weekly hemodialysis regimen
Number of subjects: 152
Study: 27770188

Group type: EXPERIMENTAL
Intervention: Saturated fat (SFA, butter)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat (PUFA, grapeseed oil)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (GI) carbohydrate (basmati rice)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-glycemic-index (GI) carbohydrate (jasmine rice)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monounsaturated fat (MUFA, olive oil)
Number of subjects: 20
Study: 27506486

Group type: EXPERIMENTAL
Intervention: Supraciliary microstenting with phacoemulsification
Number of subjects: 505

Group type: COMPARATOR
Intervention: Phacoemulsification only (control)
Number of subjects: 505
Study: 24490949

Group type: EXPERIMENTAL
Intervention: Ginger (1600 mg daily for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (1600 mg wheat flour daily for 12 weeks)
Number of subjects: 70
Study: 22539747

Group type: EXPERIMENTAL
Intervention: Remote computer-based logMAR visual acuity measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person optometrist presence
Number of subjects: 0
Study: 20435345

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinol equivalents)
Number of subjects: 207781

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207781

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 207781
Study: 17689142

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 12 weeks in addition to usual care (N=8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care (N=10)
Number of subjects: 18
Study: 16198982

Group type: EXPERIMENTAL
Intervention: 5-HT-receptor antagonists (standard dose, IV/oral)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Prochlorperazine every 8 h
Number of subjects: 691

Group type: COMPARATOR
Intervention: Prochlorperazine as needed
Number of subjects: 691
Study: 11791959

Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 76
Study: 9589243

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 15
Study: 7998769

Group type: EXPERIMENTAL
Intervention: Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immune globulin infusion
Number of subjects: 20
Study: 2897788

Group type: EXPERIMENTAL
Intervention: Glutamic acid 500 mg orally three times daily plus vincristine 1.0 mg/m2 weekly for six doses
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo plus vincristine 1.0 mg/m2 weekly for six doses
Number of subjects: 84
Study: 30726984

Group type: EXPERIMENTAL
Intervention: Tar condition
Number of subjects: 531

Group type: COMPARATOR
Intervention: No-tar condition
Number of subjects: 531
Study: 29017421

Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) by intervention pharmacists
Number of subjects: 37
Study: 26927249

Group type: EXPERIMENTAL
Intervention: Low-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, once a day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Regular-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, twice a day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (low dose and regular dose)
Number of subjects: 107
Study: 24690416

Group type: EXPERIMENTAL
Intervention: 60 mg Atomoxetine (ATX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 10 Hz rTMS and 60 mg ATX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 22332914

Group type: EXPERIMENTAL
Intervention: Diabetes scorecard
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no diabetes scorecard)
Number of subjects: 103
Study: 20836938

Group type: EXPERIMENTAL
Intervention: EMR-based prompts and education
Number of subjects: 67000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67000
Study: 18607811

Group type: EXPERIMENTAL
Intervention: Transitional Work Grant (TWG) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonparticipating companies (NTW)
Number of subjects: 0
Study: 16211736

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg and paracetamol 1.5 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo and paracetamol 1.5 g
Number of subjects: 40
Study: 11919671

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amino acid cocktail drink without tryptophan (control)
Number of subjects: 14
Study: 10978986

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 52
Study: 8658044

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (21/min by nasal prongs)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no oxygen therapy)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 89
Study: 1610863

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (cyclosporine, azathioprine, and prednisolone)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Double-drug therapy (cyclosporine and azathioprine)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Double-drug therapy
Number of subjects: 112
Study: 6734370

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg QID
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diltiazem (90, 120, 150 mg)
Number of subjects: 15
Study: 30962245

Group type: EXPERIMENTAL
Intervention: StopApp (intervention) - a brief online behaviour change intervention designed to address barriers to SSS attendance.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard promotion of and referral to SSSs (control) - standard web-based information about the SSSs.
Number of subjects: 162
Study: 29684295

Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rural residents
Number of subjects: 400

Group type: COMPARATOR
Intervention: Overall smoking prevalence
Number of subjects: 400
Study: 27107959

Group type: EXPERIMENTAL
Intervention: Novel patient information resource (website and booklet)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 24626733

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 14 mL of 0.75% ropivacaine plus 4.0 mcg/kg of clonidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural anesthesia with 14 mL of ropivacaine 0.75 % plus 0.0266 mL/kg of 0.9% saline solution
Number of subjects: 80
Study: 23092451

Group type: EXPERIMENTAL
Intervention: Weekly supplementation of 2800 μg folic acid
Number of subjects: 5011

Group type: EXPERIMENTAL
Intervention: Weekly supplementation of 60 mg iron and 2800 μg folic acid
Number of subjects: 5011

Group type: EXPERIMENTAL
Intervention: Weekly supplementation of multiple micronutrients (MM)
Number of subjects: 5011

Group type: COMPARATOR
Intervention: Current practice of prenatal IFA supplementation only
Number of subjects: 5011
Study: 21053992

Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg intravenously
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg intravenously
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg intravenously and 10 mg oral tablet (crossover)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg intravenously
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 17622876

Group type: EXPERIMENTAL
Intervention: Fixion nail (DiscOTech, Monroe Township, NJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Zimmer M/DN locked nail (Zimmer, Warsaw, IN)
Number of subjects: 20
Study: 15723872

Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Change score or percentage change score
Number of subjects: 0
Study: 11390726

Group type: EXPERIMENTAL
Intervention: Iron sucrose (250 mg iron diluted in 100 ml normal saline given over 60 min once per month)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Iron gluconate (62.5 mg iron given once per week in a slow push injection)
Number of subjects: 55
Study: 9422429

Group type: EXPERIMENTAL
Intervention: Prophylactic oral ganciclovir (1000 mg p.o. t.i.d.; n=19)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Deferred therapy (Acyclovir 200 mg p.o. b.i.d.; n=23)
Number of subjects: 42
Study: 8388275

Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent rotavirus vaccine (4 x 10^4 plaque forming units)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent rotavirus vaccine
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-breast-fed infants (comparison group)
Number of subjects: 194
Study: 2834480

Group type: EXPERIMENTAL
Intervention: PK 10169 at 0.75 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PK 10169 at 1 mg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PK 10169 at 1.25 mg/kg
Number of subjects: 42
Study: 2520420

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study: 30770931

Group type: EXPERIMENTAL
Intervention: WASH intervention (ventilated improved pit latrine, two hand-washing stations, liquid soap, chlorine, infant play space, hygiene counseling)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: WASH intervention
Number of subjects: 801
Study: 28818316

Group type: EXPERIMENTAL
Intervention: CPACS Risk Score (RS)
Number of subjects: 6790

Group type: COMPARATOR
Intervention: GRACE Risk Score (RS)
Number of subjects: 6790
Study: 26026494

Group type: EXPERIMENTAL
Intervention: CM+TAU
Number of subjects: 176

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 176
Study: 23614849

Group type: EXPERIMENTAL
Intervention: Co-managed intervention
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Diuretic added during first month
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374
Study: 21406599

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19095506

Group type: EXPERIMENTAL
Intervention: Ketamine-clonidine infusion before anesthesia induction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard anesthesia
Number of subjects: 50
Study: 16549465

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25.8% of energy intake from fat)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid (MUFA) diet (40.1% of energy intake from fat, 22.5% from MUFA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 14695735

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 2703

Group type: COMPARATOR
Intervention: Intravenous meperidine analgesia
Number of subjects: 2703
Study: 11767175

Group type: EXPERIMENTAL
Intervention: Silzone-coated valves
Number of subjects: 95

Group type: COMPARATOR
Intervention: Uncoated valves
Number of subjects: 95
Study: 9268955

Group type: EXPERIMENTAL
Intervention: Chromium nicotinate supplementation with exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 0
Study: 8261775

Group type: EXPERIMENTAL
Intervention: MULCOX2 program for Cox regression analysis
Number of subjects: 0
Study: 3543049

Group type: EXPERIMENTAL
Intervention: Propranolol (180 or 240 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31146305

Group type: EXPERIMENTAL
Intervention: Functional Training Group (FTG)
Number of subjects: 39
Study: 28648913

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release b.i.d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg extended release b.i.d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26556692

Group type: EXPERIMENTAL
Intervention: One year of free school fruit (daily one piece of fruit or vegetable)
Number of subjects: 320
Study: 23238152

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 105607
Study: 21531512

Group type: EXPERIMENTAL
Intervention: Intrauterine surgical intervention for closure of the vertebral defect
Number of subjects: 0
Study: 19894656

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from the first visit (HTN1)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from the second visit (HTN2)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from both visits (HTN(Final))
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Awareness based on first visit
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Treatment based on first visit
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Control based on first visit
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: HTN(Final) with body mass index > or = 30
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: HTN(Final) with left ventricular hypertrophy
Number of subjects: 739
Study: 16434649

Group type: EXPERIMENTAL
Intervention: Virtual reality visual-feedback cues
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study: 14628989

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Paroxetine 60 mg/day
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Paroxetine (any dose)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 348
Study: 11405344

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐Gal A (r‐halphaGal A) replacement therapy for Fabry disease
Number of subjects: 0
Study: 9404906

Group type: EXPERIMENTAL
Intervention: Cefixime (10 mg/kg to 12 mg/kg per day in two divided doses)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg daily in four divided doses)
Number of subjects: 85
Study: 8388231

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus verapamil (480 mg day‐1 for 3 days prior to chemotherapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 72
Study: 3317054

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg every six hours for 24 hours)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30694963

Group type: EXPERIMENTAL
Intervention: Fat Gripz (FG)
Number of subjects: 15
Study: 31364266

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 28838583

Group type: EXPERIMENTAL
Intervention: Oral Aripiprazole 10 to 30 mg/d
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 26614965

Group type: EXPERIMENTAL
Intervention: PrEP with oral emtricitabine and tenofovir disoproxil fumarate
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 23335369

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment with MYC, BCL2, and BCL6 rearrangements and protein expression analysis
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Combined immunohistochemical or FISH/immunohistochemical score
Number of subjects: 442
Study: 21569539

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (no anti-epileptic drugs)
Number of subjects: 112
Study: 19229428

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 16543098

Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine (0.2 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 30
Study: 14597934

Group type: EXPERIMENTAL
Intervention: β-blocker therapy for CHF
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10912311

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-hormonal and hormonal agents
Number of subjects: 0
Study: 9238869

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean (ID2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 48
Study: 1740203

Group type: EXPERIMENTAL
Intervention: Zona drilling procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 20